Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows - STAT
- Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows STAT
- An experimental Alzheimer's drug shows some promise as researchers hunt new approaches AP News
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease Biogen
- Biogen Shares Fall as Alzheimer’s Tau Trial Data Disappoint Bloomberg.com
- AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline Fierce Biotech
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events